Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
about
Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerSerum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis.The best of both worlds - managing the cancer, saving the bone.Evolving role of bone biomarkers in castration-resistant prostate cancer.Bone metastasis: mechanisms and therapeutic opportunities.Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.An atypical presentation of breast cancer metastasisCancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogsDiagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysisEffects of sangu decoction on osteoclast activity in a rat model of breast cancer bone metastasisStathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro.Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors.Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis.RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.RANKL: A promising circulating marker for bone metastasis responseBisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile report.Clinical usefulness of bone markers in prostate cancer with bone metastasis.Laboratory methods and biomarkers in the evaluation of bisphosphonate effects on body tissues: a literature review.Biomarkers of bone turnover in oncology: applications in diagnosis and treatment.A short account of metastatic bone disease.Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics.De-escalation of bone-targeted agents for metastatic prostate cancerShould de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.The value of biomarkers in bone metastasis.The role of biomarkers in the management of bone-homing malignancies.Effect of dimethyl sulfoxide on inhibition of post-ovariectomy osteopenia in rats.Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study.High uric acid (UA) downregulates bone alkaline phosphatase (BALP) expression through inhibition of its promoter activity.Prediction of skeletal-related events in patients with non-small cell lung cancer.SEOM guidelines for the treatment of bone metastases from solid tumours.RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
P2860
Q28079918-5C5DC9F7-882A-45ED-AD21-5BEF5843118DQ33563273-9605F1E6-944E-4A93-B4C5-269EBFF4B957Q33920055-81BEDC39-FB0B-4218-9BA7-4791B83611BEQ34023877-941DDD77-3F8D-4D43-BA5B-67E0E2C63A94Q34025195-36EFA069-41FC-47D2-A88B-08DEFF6F3CE9Q34325491-48388D49-848C-4E6C-976B-595BED0C8CDCQ34522780-B9D5D7C1-A528-4A46-ADCC-7A4CD3DE0AE9Q35156035-F111BA10-79C4-41E2-8BFD-A810B8BDF9DAQ35894852-89C8AB30-1C2A-405C-AA9B-92F7F94A1070Q36446782-DA9FA5BA-B7E1-481C-8F4C-55B018E7E4A9Q36491391-204F13BE-816F-4382-AEB1-1626D1023629Q36516278-93F2D6EC-3A74-4338-9434-C3A3130D735DQ36837041-815A7D5D-433B-446A-90BD-A6DAE448A6E7Q37007044-E157EFA4-5607-40A3-8C5B-3AD010A35D59Q37288243-8AB9557A-29E5-4B77-A6B5-CE66BD58B678Q37403207-693E3EC0-549C-4AC6-8D4D-E09F8B3E8EAFQ37888670-CDEDB70E-C820-494D-9578-7BA880D62910Q37952289-8FF5DA28-383E-4316-89AB-343C358DD08AQ38026966-6235B364-5A0E-4E85-9713-A3CFD00558E0Q38070779-AB9D5E6A-BDF5-4581-87AE-8458C00E35B2Q38088714-8291BDDC-542C-4CF7-990E-A0F201639EFDQ38255403-A31D38BF-D1D4-4A13-9217-55CC0958E2DDQ38263353-BCF4733D-D663-4985-954E-C9C267DCB68BQ38452402-57537443-1313-48FF-B1EF-7C1063B62BD6Q38540093-EB4A3043-E8E1-4962-BF01-F66C75569DC3Q38693661-DD354865-7680-4E12-8E2A-5D0D100EFB41Q38703298-259824BC-01B9-435B-8986-8A34412FBFFCQ39311670-C3C3151B-507C-4A6B-82D5-0950BEC616DDQ39400189-9BE914B2-D5A0-4183-949C-97939370AE2EQ41692580-15CEB0C8-5500-4BB7-8582-0282564CD327Q44421391-E92DAD2D-77DD-41CF-9FE0-F951E8E5C857Q45235765-2AD4128C-090C-4E67-9D6B-A0419AACFFC6Q46691665-2EE22068-78EB-44E5-B358-334900FEEC44Q47155205-8A10FD63-009C-4B29-8E92-DA9CF5386AD9Q47797871-C5A218E4-EB5F-4C49-AB07-E368A19EF18AQ51352205-D0093CF8-E295-478F-A75E-DE4D9F06BD79Q57904702-E3DE681F-6504-4311-BF4D-438B26A6A771
P2860
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Bone markers and their prognos ...... vidence and future directions.
@ast
Bone markers and their prognos ...... vidence and future directions.
@en
Bone markers and their prognos ...... vidence and future directions.
@nl
type
label
Bone markers and their prognos ...... vidence and future directions.
@ast
Bone markers and their prognos ...... vidence and future directions.
@en
Bone markers and their prognos ...... vidence and future directions.
@nl
prefLabel
Bone markers and their prognos ...... vidence and future directions.
@ast
Bone markers and their prognos ...... vidence and future directions.
@en
Bone markers and their prognos ...... vidence and future directions.
@nl
P2093
P2860
P1476
Bone markers and their prognos ...... vidence and future directions.
@en
P2093
Allan Lipton
Evangelos Terpos
Janet Brown
Matthew R Smith
Pierre Major
Richard Cook
Robert Coleman
P2860
P304
P356
10.1016/J.CTRV.2008.05.001
P577
2008-06-24T00:00:00Z